IGF-1 Receptor α/IGF1R Antibody (2C8): sc-463

IGF-IRα Antibody (2C8) is a mouse monoclonal IgG1 kappa light chain antibody that detects IGF-IRα in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. IGF-IRα monoclonal antibody (2C8) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The insulin-like growth factor-I receptor (IGF-IR) plays a crucial role as a receptor tyrosine kinase, influencing vital cellular processes such as growth, survival, and differentiation. Located on the cell membrane, IGF-IRα is essential for mediating the effects of insulin-like growth factor-I (IGF-I), which promotes cell proliferation and inhibits apoptosis, making IGF-IRα a significant player in growth hormone signaling pathways. IGF-IR activation leads to the recruitment of adaptor proteins like Shc, GRB2, and Sos 1, initiating downstream signaling cascades that activate Ras and ERK kinases, ultimately affecting transcription factor activity. Additionally, the insulin receptor substrate (IRS)-1 and -2 proteins interact with active IGF-IR, triggering phosphatidylinositol 3-kinase-dependent signaling pathways that are critical for cellular responses to growth factors. The human IGF-IR gene is located on chromosome 15q26.3 and encodes a precursor protein of 1,376 amino acids, which is cleaved into α and β subunits, highlighting IGF-IR complexity and importance in cellular signaling and cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IGF-1 Receptor α/IGF1R Antibody (2C8) References:

1. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane.  |  Song, RX., et al. 2004. Proc Natl Acad Sci U S A. 101: 2076-81. PMID: 14764897
2. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.  |  Mitsiades, CS., et al. 2004. Cancer Cell. 5: 221-30. PMID: 15050914
3. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.  |  Salatino, M., et al. 2004. Oncogene. 23: 5161-74. PMID: 15122317
4. IL-1beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts.  |  Broussard, SR., et al. 2004. J Immunol. 172: 7713-20. PMID: 15187154
5. Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells.  |  Hayashi, K., et al. 2004. J Biol Chem. 279: 40807-18. PMID: 15272025
6. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis.  |  Shimizu, C., et al. 2004. Hum Pathol. 35: 1537-42. PMID: 15619214
7. Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling.  |  De Meyts, P., et al. 1995. Ann N Y Acad Sci. 766: 388-401. PMID: 7486684
8. Molecular defects of insulin/IGF-1 receptor transmembrane signaling.  |  Frattali, AL. and Pessin, JE. 1993. Ann N Y Acad Sci. 687: 77-89. PMID: 8323192
9. Insulin and IGF-I signaling through the insulin receptor substrate 1.  |  Keller, SR., et al. 1993. Mol Reprod Dev. 35: 346-51; discussion 351-2. PMID: 8398112

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IGF-1 Receptor α/IGF1R Antibody (2C8) has 35 citations in a variety of scientific publications.

Primary antibodies like Anti-IGF-1 Receptor α/IGF1R Antibody (2C8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IGF-1 Receptor α/IGF1R Antibody (2C8) Specifications

Alternate Product Name: IGF1R

Product Clone Name: 2C8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: IGF-IRα

Epitope Species: human

Product Reactivity/Detection: IGF-IRα and complex

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 35 citations in various scientific publications

Available Conjugates/Forms for IGF-1 Receptor α/IGF1R Antibody (2C8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin